1. Home
  2. IDYA vs PCH Comparison

IDYA vs PCH Comparison

Compare IDYA & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$34.38

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo PotlatchDeltic Corporation

PCH

PotlatchDeltic Corporation

HOLD

Current Price

$40.05

Market Cap

3.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
PCH
Founded
2015
1903
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.0B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IDYA
PCH
Price
$34.38
$40.05
Analyst Decision
Strong Buy
Hold
Analyst Count
13
6
Target Price
$49.18
$45.67
AVG Volume (30 Days)
943.7K
537.1K
Earning Date
02-12-2026
01-26-2026
Dividend Yield
N/A
4.51%
EPS Growth
N/A
312.61
EPS
N/A
0.82
Revenue
$214,834,000.00
$1,115,571,000.00
Revenue This Year
$2,662.86
$3.66
Revenue Next Year
N/A
$1.27
P/E Ratio
N/A
$48.68
Revenue Growth
5377.66
5.40
52 Week Low
$13.45
$36.82
52 Week High
$37.08
$48.12

Technical Indicators

Market Signals
Indicator
IDYA
PCH
Relative Strength Index (RSI) 52.00 51.39
Support Level $33.11 $39.02
Resistance Level $34.45 $40.35
Average True Range (ATR) 1.14 0.93
MACD -0.08 0.01
Stochastic Oscillator 44.14 39.24

Price Performance

Historical Comparison
IDYA
PCH

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About PCH PotlatchDeltic Corporation

PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.

Share on Social Networks: